(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
An eye for an eye: People agree about the values of body parts across cultures and eras - 2South Carolina's measles outbreak reaches 434 cases
- 3I tried a macho, creatine-loaded cereal “for men.” Did I mention I'm a woman?
- 4Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- 5Home Mechanization Frameworks for Brilliant Residing
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Zelensky names spy chief to head presidential office after corruption row
- The Most Important Crossroads in Olympic History
- Purchases of iPhone 17 Pro soar across Gaza amid 'limited' humanitarian aid
- How will the universe end?
- Video Conferencing Instruments for Virtual Gatherings
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- Is Trump going to war with Venezuela?
